


# hcoosier<sup>SM</sup>

CANCER RESEARCH NETWORK



# Annual Report 2017

# Board of Directors



## Appointed Director


Christopher Fausel, PharmD, *Chair*  
Charles Fox  
Patrick Loehrer, Sr., MD  
Bert O'Neil, MD, *Chief Scientific Officer*  
Timothy Ratliff, PhD  
Richard Zellars, MD

## Elected Director

Sumeet Bhatia, MD  
Kerry Bridges, MBA, RN, CCRC  
Noah Hahn, MD  
Christopher LeMasters, MBA  
Annette Moore, MD, *Secretary*  
Ted Stansbury  
Christopher Wayne, MS, MBA, FACHE, CMPE, *Treasurer*

Hoosier Cancer Research Network's vision and mission is to form **unparalleled** relationships between academic, community, pharmaceutical, and biotech partners with the goal of **advancing** cancer research, education, and patient advocacy.

Our **highly qualified** team provides **comprehensive** study management and support, from conception and study design through project completion and publication.





# A message from our Chairman of the Board

**T**wenty-seventeen was an extraordinary year of growth for HCRN — both in terms of numbers and in the quality of engagement with our network collaborators.

More top academic research institutions and key opinion leaders joined our network in 2017, enriching the scientific strength and energy of each of our disease-specific clinical trial working groups. The best kept secret in clinical research is quickly evaporating as investigators invite their colleagues to join our network. We are increasingly viewed by top academic institutions as a preferred research collaborator for multi-center investigator-initiated studies.

This growth enables us to pursue more aggressively than ever our highest goal: to help our patients live longer and healthier lives.

Each investigator, bench scientist, oncology nurse, pharmacist, and study coordinator throughout our network knows that patients are the heart and soul of our work. As an outgrowth of our mission, HCRN is committed not only to the timely completion of primary endpoints, but also to exploring answers to key correlative questions. The more we learn about a patient's genetic profile, the micro-environment of their tumor, and the effect of an investigational therapy on patients with similar characteristics, we can make more timely, informed decisions that could benefit our patients or spare them from what would be an ineffective treatment approach.

HCRN negotiates with funders and investigators to include correlative objectives within our study budgets to the fullest extent possible. Yet, important correlative studies are often outside the scope of a clinical trial budget. For that reason, HCRN relies on the generosity of individuals, businesses, and philanthropic organizations to fill the gap in funding these important studies. Every donation or grant we receive moves us further down the road of scientific discovery. To all those who contributed in 2017, and to those who are already contributing in 2018 — thank you for making a difference for our patients!

I am proud of the dedicated and knowledgeable staff at HCRN for their contributions to an outstanding year.



**Christopher A. Fausel,  
PharmD, MHA, BCOP**

Clinical Manager, Oncology Pharmacy  
Indiana University School of Medicine



# A message from our Chief Scientific Officer



## **Bert H. O'Neil, MD**

Cusick Professor of Oncology  
Director, Phase I & GI Oncology  
Indiana University School of Medicine

Veterans of clinical research know that we have entered a new era in which clinical trials are more targeted than ever to specific, biomarker-defined patient populations. This shift reflects the greater trend in healthcare toward personalized therapy, and is evidenced in the concepts that come to HCRN.

Investigators understand that clinical trials based on biomarker-selected subgroups are difficult to fully accrue, and can only succeed when conducted via collaboration across multiple institutions. An example of this can be seen in studies that involve immunotherapeutic agents for certain subgroups of patients, such as patients with microsatellite instability-high (MSI-H) colorectal cancer, representing just 3 percent of all metastatic colorectal cancers.

To our investigators, HCRN brings not only the wisdom gained from more than three decades of multi-center investigator-initiated research, but also a responsive organizational culture that quickly adapts to the changing horizon of medical research. Only a few years ago, immunotherapy was just entering the clinical research milieu. Today, more than 60 percent of HCRN studies involve immunotherapy.

HCRN's clinical trial working groups provide an ideal venue for investigators to test their concepts in a supportive, collegial environment. Our personal style of engagement allows young investigators to learn from the experience of thought

leaders from the nation's leading academic institutions, while providing a venue for all investigators to receive valuable scientific feedback on their research proposals. The growth of our investigator network is leading to more clinical trials in more therapeutic areas, in both solid tumor and hematologic malignancies.

Of course, none of this would be possible without strong relationships with funders. Each year, the number of pharmaceutical and biotech companies with whom we collaborate increases. And more and more, these companies return to conduct additional studies with HCRN.

We are grateful, as well, to the foundations and advocacy groups that support our studies. In fact, we are nearing completion of a personalized medicine study in breast cancer that has been fully funded through foundation grants. Another organization is funding a banking and genomic sequencing study in bladder cancer.

To all our members and collaborators, thank you for your partnership with HCRN. We look forward to continuing our work together in 2018.

A handwritten signature in black ink, appearing to read "Bert", is centered within a white circular graphic element. The signature is fluid and cursive.

## Sandra Turner Excellence in Clinical Research Award

“**B**eing a clinical research specialist, I find that there is no boring day; every day is new. You learn every day, you work through medical records, and if there is anything in question, you research it and try to find answers. You ask your PI, research nurse, and your team for answers along the way. Each patient experience gives you knowledge.

Some of the trials we have are survival studies, so you follow these patients for a long time and you get to know the family. There are patients from many years ago that still come to my office to see me.

”

### 2017 Recipient Rhoda Loman

Clinical Research Specialist,  
Indiana University  
Melvin and Bren Simon Cancer Center



### About the Award

The Sandra Turner Excellence in Clinical Research Award was established in 2002 by William B. Fisher, MD, through the George and Sarah Jane Fisher Fund to honor the memory of Sandra Turner, the first executive director of Hoosier Cancer Research Network. Recipients exemplify qualities which Sandra Turner possessed, such as sustained professional commitment, contribution to the progress of oncology care, and unflinching compassion.

# Honoring Excellence

## Sandra Turner Excellence in Clinical Research Award

“**T**o really make a difference for patients, we have to figure out how to detect or treat their disease, or prevent it in the first place. It takes understanding how things work to target them. That’s part of the reason why clinical trials are so important. The faster we are able to get answers to questions, the faster we can do things that we know really make a difference for patients.

Oncology care is not for the faint of heart. It can be filled with a lot of joy, but there are really sad moments. Having a way to manage those emotions and acknowledge them allows you to be there for a family or patient that’s going through this. Every time is their first time, and you have to really pay attention to that.”

### 2017 Recipient

#### Maggie Urich, RN, BSN, OCN

Thoracic Oncology Research Nurse,  
Indiana University  
Melvin and Bren Simon Cancer Center




### About the Award

The Sandra Turner Excellence in Clinical Research Award was established in 2002 by William B. Fisher, MD, through the George and Sarah Jane Fisher Fund to honor the memory of Sandra Turner, the first executive director of Hoosier Cancer Research Network. Recipients exemplify qualities which Sandra Turner possessed, such as sustained professional commitment, contribution to the progress of oncology care, and unflinching compassion.

# Honoring Excellence

## George and Sarah Jane Fisher Young Investigator Award

“**G**enitourinary malignancies are very diverse cancers, making GU oncology a very exciting field. Right now, I’m working on a variant of bladder cancer, plasmacytoid urothelial carcinoma, that has a very poor outcome compared to the common urothelial carcinoma. I have collected a cohort of patients and analyzed their responses to a variety of treatments. We are sending those patients to our precision genomics clinic to look for possible targetable mutations. We are also doing epigenomic (methylation) assays and chromatin analysis to compare the plasmacytoid carcinomas with the common urothelial carcinomas. If any DNA hypermethylation is found, then we could try combining immune checkpoint inhibitors or chemotherapy with a hypomethylating agent.”



### 2017 Recipient **Neda Hashemi Sadraei, MD**

Third-year fellow; chief fellow in  
hematology/oncology,  
Indiana University School of Medicine

#### About the Award

In 2011, William B. Fisher, MD and others generously established a new award through the George and Sarah Jane Fisher Fund to challenge the next generation of cancer researchers. The George and Sarah Jane Fisher Young Investigator Award honors Indiana University oncology fellows and faculty members who have made significant contributions to clinical or basic science research in collaboration with Hoosier Cancer Research Network.

# Honoring Excellence



## Terry Hoepfner Patient Advocacy Award

“**W**ith cancer comes recognition of the fact that death is real, that you only are blest with so many days, and you only have so much time. But you also realize that you get to make choices about how you spend this measured time. When my diagnosis came, I decided how I wanted to spend this time — I chose advocacy and art.

I sit here most likely alive today because of having made a decision to go into a clinical trial. ... I'm such a believer that these trials will be what will cure cancer, I have no question it will happen. But it is only when people raise their hand and say, 'I will do my part,' that it happens.”

### 2016-2017 Recipient **Teresa Altemeyer**

Patient advocate;  
board chair, Indiana Chapter of the  
Leukemia & Lymphoma Society



#### About the Award

Terry Hoepfner, beloved Indiana University football coach, lost his battle with brain cancer in 2007. Coach Hep was known for his “never quit” attitude and determination to face challenges head-on. To honor his memory, his wife, Jane Hoepfner, created the Terry Hoepfner Patient Advocacy Award. The award honors individuals who embody Coach Hep’s spirit and determination to champion their cause.



# Publications & Abstracts

## GI14-186

### **A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.**

*J Clin Oncol 35, 2017 (suppl; abstr 3541)*

**Authors:** Safi Shahda, Anne M. Noonan, Tanios S. Bekaii-Saab, Bert H. O'Neil, Amikar Sehdev, Walid Labib Shaib, Paul R. Helft, Patrick J. Loehrer, Yan Tong, Ziyue Liu, Bassel F. El-Rayes; Indiana University, Indianapolis, IN; The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Columbus, OH; Mayo Clinic Cancer Center, Phoenix, AZ; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Winship Cancer Institute, Atlanta, GA; Indiana University School of Medicine, Indianapolis, IN

## GU10-148

### **DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).**

*J Clin Oncol 35, 2017 (suppl 6S; abstract 300)*

**Authors:** Matt D. Galsky, Andrew V. Uzilov, Russell Bailey McBride, Huan Wang, Vaibhav G. Patel, John Sfakianos, Li Wang, Nicholas Akers, Gopa Iyer, David B. Solit, Takuro Saito, Mireia Castillo-Martin, Noah M. Hahn, Sumanta K. Pal, Mark T. Fleming, Ralph J. Hauke, Bojan Losic, Sacha Gnjatic, Rong Chen, Nina Bhardwaj; Icahn School of Medicine at Mount Sinai, New York, NY; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY; Genetics and Genomic Sciences, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY; Johns Hopkins University, Baltimore, MD; City of Hope, Duarte, CA; US Oncology Research, Virginia Oncology Associates, Hampton, VA; Nebraska Cancer Specialists, Omaha, NE; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

## GU12-159

### **PACIFIC trial: A randomized phase II study of apatersen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI).**

*J Clin Oncol 35, 2017 (suppl 6S; abstract 146)*

**Authors:** Kim N. Chi, Mark T. Fleming, Katherine Sunderland, Costantine Albany, Joel Gingerich, Fred Saad, Scott A. North, Alexander Starodub, Richard C. Lauer, Joseph D. Ruether, Madelaine Miranda Sgroi, Mark C. Scholz, Christopher Sweeney; British Columbia Cancer Agency, Vancouver, BC, Canada; US Oncology Research, Virginia Oncology Associates, Hampton, VA; BC Cancer Centre, Vancouver, BC, Canada; Indiana University School of Medicine, Indianapolis, IN; CancerCare Manitoba, Winnipeg, MB, Canada; University of Montreal, Montreal, QC, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Indiana University Health Goshen Center for Cancer Care, Goshen, IN; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; Tom Baker Cancer Center, Calgary, AB,

Canada; Central Indiana Cancer Center, Indianapolis, IN; Prostate Oncology Specialists, Marina del Rey, CA; Dana-Farber Cancer Institute, Boston, MA

## GU12-160

### **Borealis-2: A randomized phase II study of OGX-427 (apatersen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer Research Network GU12-160).**

*J Clin Oncol 35, 2017 (suppl 6S; abstract 289)*

**Authors:** Toni K. Choueiri, Noah M. Hahn, Lillian Werner, Meredith M. Regan, Jonathan E. Rosenberg, BOREALIS-02 investigators; Dana-Farber/Harvard Cancer Center, Boston, MA; Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY

## GU14-206

### **Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT).**

*J Clin Oncol 35, 2017 (suppl; abstr 4520)*

**Authors:** Nabil Adra, Sandra K. Althouse, Natraj Reddy Ammakkanavar, Milan Radovich, Costantine Albany, David J. Vaughn, Lawrence H. Einhorn, Nasser H. Hanna; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Community Cancer Center, Indianapolis, IN; Abramson Cancer Center, Philadelphia, PA

## LUN14-179

### **Safety and feasibility of consolidation pembrolizumab following concurrent chemoradiation for unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN14-179.**

*J Clin Oncol 35, 2017 (suppl; abstr 8523)*

**Authors:** Greg Andrew Durm, Cynthia Johnson, Shadia Ibrahim Jalal, Ahad Ali Sadiq, Salma Jabbour, Robin Zon, Goetz H. Kloecker, Karen L. Reckamp, William B. Fisher, Nasser H. Hanna; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University Department of Biostatistics, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Michiana Hematology Oncology, PC, South Bend, IN; University of Louisville, Louisville, KY; City of Hope Comprehensive Cancer Center, Duarte, CA; Medical Consultants, Muncie, IN

See all HCRN publications at:

[hoosiercancer.org/category/publications/](https://www.hoosiercancer.org/category/publications/)

# Our Member Network

## Alabama

- UAB Comprehensive Cancer Center, Birmingham

## Arizona

- BCG Oncology, P.C., Phoenix
- Ironwood Cancer & Research Centers, Phoenix
- Mayo Clinic, Phoenix
- University of Arizona Cancer Center at Dignity Health St. Joseph's, Phoenix
- Yuma Regional Cancer Center, LLC, Yuma

## Arkansas

- Genesis Cancer Center, Hot Springs

## California

- Cedars-Sinai Medical Center, Los Angeles
- City of Hope, Duarte
- Marin Specialty Care, Greenbrae
- Moore's Cancer Center at UC San Diego Health, San Diego
- Prostate Oncology Specialists, Inc., Marina Del Rey
- Salinas Valley Memorial Healthcare System, Salinas
- USC Norris Comprehensive Cancer Center, Los Angeles

## Colorado

- University of Colorado Cancer Center, Aurora

## Florida

- Memorial Breast Cancer Center at Memorial Regional Hospital, Hollywood
- UF Health Cancer Center at Orlando Health, Orlando
- Moffitt Cancer Center, Tampa
- University of Florida Health Cancer Center, Gainesville
- University of Miami, Miami

## Georgia

- Winship Cancer Institute of Emory University, Atlanta

## Illinois

- Illinois CancerCare, PC, Galesburg
- Oncology Specialists, S.C., Niles
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
- University of Illinois Cancer Center, Chicago

## Indiana

- Community Healthcare - Primary Care Oncology, Munster
- Community Hospital of Anderson and Madison County, Inc., Anderson
- Community Regional Cancer Centers, Indianapolis
- Floyd Memorial Cancer Center of Indiana, New Albany
- Fort Wayne Medical Oncology & Hematology, Fort Wayne
- Good Samaritan Hospital, Vincennes
- Goshen Center for Cancer Care, Goshen
- Hope Center, Terre Haute
- Horizon Oncology Research, Inc., Lafayette
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Arnett Cancer Centers, Lafayette
- IU Health Ball Memorial Hospital Cancer Center, Muncie
- IU Health Cancer Centers Bloomington, Bloomington
- IU Health Central Indiana Cancer Centers, Indianapolis
- Jasper Memorial Hospital, Jasper
- Kosciusko Community Hospital Cancer Care Center, Warsaw
- Oncology Hematology Associates of SW Indiana, Newburgh
- Radiation Oncology Associates, Fort Wayne
- St. Vincent Anderson Regional Hospital, Anderson

- St. Vincent Health, Indianapolis
- Union Hospital, Inc., Terre Haute

## Iowa

- Holden Comprehensive Cancer Center, University of Iowa, Iowa City

## Kansas

- Cancer Center of Kansas, Wichita

## Kentucky

- University of Louisville, Louisville

## Louisiana

- LSU Health Care Center, Houma
- Ochsner Clinic Foundation, New Orleans

## Maryland

- Meritus Center for Clinical Research / John R. Marsh Cancer Center, Hagerstown
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore

## Massachusetts

- Dana-Farber Cancer Institute, Boston
- Tufts Medical Center, Boston

## Michigan

- Barbara Ann Karmanos Cancer Center, Detroit
- The Cancer Center at Metro Health Village, Wyoming
- Henry Ford Health System, Detroit
- Michigan Center of Medical Research, Farmington Hills
- University of Michigan Comprehensive Cancer Center, Ann Arbor

## Minnesota

- HealthPartners Institute, Minneapolis
- Masonic Cancer Center, University of Minnesota, Minneapolis
- Mayo Clinic, Rochester

## Missouri

- Washington University School of Medicine / Siteman Cancer Center, St. Louis

## Nebraska

- GU Research Network, LLC, Omaha
- Nebraska Cancer Specialists, Omaha
- Nebraska Methodist Hospital, Omaha

## New Hampshire

- Dartmouth-Hitchcock Norris Cotton Cancer Center, Lebanon

## New Jersey

- Atlantic Health System, Morristown
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
- Penn Medicine | Virtua Cancer Program - Mount Holly Regional Cancer Care Associates, LLC, Cherry Hill
- Rutgers Cancer Institute of New Jersey, New Brunswick


## New Mexico

- University of New Mexico Cancer Center (NMCCA), Albuquerque

## New York

- Columbia University Medical Center, New York
- Integrated Medical Professionals, PLLC, Melville
- Tisch Cancer Institute at Mount Sinai, New York

# Our Member Network



Learn more at:  
[hoosiercancer.org/  
our-network/](https://hoosiercancer.org/our-network/)

- Memorial Sloan Kettering Cancer Center, New York
- New York University Cancer Institute, New York
- Roswell Park Cancer Institute, Buffalo
- University of Rochester Medical Center, Rochester

## North Carolina

- Comprehensive Cancer Center of Wake Forest University, Winston-Salem
- Novant Health Oncology Specialists, Winston-Salem
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

## Ohio

- Cleveland Clinic Taussig Cancer Institute, Cleveland
- The Ohio State University, Columbus
- University of Cincinnati Cancer Institute, Cincinnati
- University Hospitals Seidman Cancer Center, Cleveland

## Oklahoma

Mercy Clinic Oncology and Hematology - McAuley, Oklahoma City

## Oregon

- Oregon Health & Sciences University, Portland
- Providence Cancer Center, Portland

## Pennsylvania

- Fox Chase Cancer Center, Philadelphia
- Gettysburg Cancer Center, Gettysburg
- PinnacleHealth Cancer Care, Harrisburg
- Thomas Jefferson University / Sidney Kimmel Cancer Center, Philadelphia
- University of Pennsylvania, Philadelphia

## South Carolina

- Medical University of South Carolina / Hollings Cancer Center, Charleston

## Tennessee

- Erlanger Health System, Chattanooga
- Vanderbilt-Ingram Cancer Center, Nashville
- West Cancer Center, Memphis

## Texas

- Baylor College of Medicine - Methodist Breast Center, Houston
- Cancer Therapy & Research Center at UT Health Science Center, San Antonio
- Joe Arrington Cancer Research and Treatment Center, Lubbock
- MD Anderson Cancer Center, Houston
- Medicus Alliance Clinical Research, Houston
- Texas Oncology PA, Dallas
- UT Medical Branch at Galveston, Galveston
- UT Southwestern Medical Center, Dallas

## Utah

- Huntsman Cancer Institute at Univ. of Utah, Salt Lake City

## Virginia

- University of Virginia Cancer Center, Charlottesville
- Virginia Oncology Associates, Norfolk

## Washington

- University of Washington, Seattle

## Washington, D.C.

- George Washington University Cancer Center
- Georgetown University Medical Center

## Wisconsin

- Aurora Research Institute, LLC, Milwaukee
- Clement J. Zablocki VA Medical Center, Milwaukee
- Froedtert & the Medical College of Wisconsin, Milwaukee
- University of Wisconsin Carbone Cancer Center, Madison

# Our Contributors



**T**hank you to all who have contributed to Hoosier Cancer Research Network. We are grateful for your commitment of time and resources to help us fulfill our mission. Your generous support strengthens our ability to fund investigator-initiated research. Learn how YOU can contribute to cancer research at [www.hoosiercancer.org/make-a-difference/](http://www.hoosiercancer.org/make-a-difference/).

## Contributions Received in 2017

Rafat Abonour  
AmazonSmile  
Ansari Charitable Foundation  
JoLynn Bahr  
Brent Barta  
John Baute — *in memory of Bill and Marie Wood*  
Cynthia Burkhardt — *in memory of John Waffle*  
David and Stacey Cadogan  
Kenneth Cornetta  
Chris Dafforn  
Randy Dillinger  
Karen Dutcher — *in memory of Glennon Schlueter*  
Elizabeth Edwards — *in honor of William B. Fisher*  
Sylvia J. Edwards — *in honor of William Fisher*  
Christopher Fausel — *in honor of William B. Fisher*  
David Fisher — *in memory of Sarah Jane Fisher;*  
*in honor of William B. Fisher*  
John E. Fisher, Jr. — *in memory of George and*  
*Sarah Jane Fisher*  
William B. Fisher  
Charlie Fox  
Sara Grethlein  
Pamela Griffin — *in memory of Carolee Ford*  
Patricia Kneebone  
Ahran Lee  
Chris LeMasters


Kennda Lynch — *in memory of Shirley Boyle*  
R.V. Prasad Mantravadi  
Cara Martin — *in memory of Skip Herring*  
Rakesh Mehta  
Stephen and Cathie Miller — *in honor of*  
*William B. Fisher*  
Nicole Morgan — *in memory of Tony Hayden*  
John Nell  
Network for Good  
Bert O'Neil  
Maria Piddoubny  
Gregory Reimann  
Megan Reimann  
Jessica Roy  
Daniel Rushing  
James and Cathy Schrecongost — *in honor of*  
*William B. Fisher*  
Safi Shahda — *in memory of Laurette Abkarian*  
Thomas Sibert  
Kelly and Donna Stanley — *in honor of William B. Fisher*  
Cathy Usher — *in memory of Sally Thrasher*  
Doug Vaughan  
Nino Voskuhl  
Lisa Wood — *in memory of William Wood*  
Christopher Wu  
Your Cause (AT&T)

Did you know you can support HCRN through purchases made through Amazon Smile? When you shop, Amazon will donate a portion of your purchase cost to HCRN. Scan the code to the right or visit <https://smile.amazon.com/ch/26-0303542> to get started!



# hcosier<sup>SM</sup>

CANCER RESEARCH NETWORK



500 N. Meridian Street, Suite 100, Indianapolis, IN 46204

**P:** (317) 921-2050 **F:** (317) 921-2053 **E:** [contact@hoosercancer.org](mailto:contact@hoosercancer.org)

[www.hoosercancer.org](http://www.hoosercancer.org)